tm logo
SUN PHARMA & DESIGN
REGISTERED

on 01 Oct 2019

Last Applicant/ Owned by

SUN PHARMACEUTICAL INDUSTRIES LIMITED

Sun House, Plot No. 201 B/1, Western Express Highway, Goregaon (E), Mumbai 400063

IN

Serial Number

1835874 filed on 04th May 2017

Registration Number

TMA1056964 registered on 01st Oct 2019

Registration expiry Date

01st Oct 2029

SUN PHARMA & DESIGN

Vienna Information


1 . 15 . 23

Vortices, rotary movements, tornadoes -- Note: Not including astronomic orbits (1.13.1), atomic orbits (1.13.1), concentric circles (26.1.4 or 26.1.5) and spirals (26.1.5).Tourbillons, mouvements rotatifs, tornade -- Note: Non compris les orbites astronomiques (1.13.1), les orbites atomiques (1.13.1), les cercles concentriques (26.1.4 ou 26.1.5) et les spirales (26.1.5).

1 . 7 . 19

Several crescents or half-moonsPlusieurs croissants ou demi-lunes

1 . 3 . 2

Other representations of the sunAutres représentations du soleil

Trademark usage description

pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, a Read More

Classification Information


Class [005]
Pharmaceutical preparations for the prevention and treatment of psychiatric diseases, degenerative nerve diseases and brain disorders, namely, mood, anxiety, schizophrenia and cognitive disorders, Alzheimer's disease, cerebral palsy, Parkinson's disease, Huntington's disease and multiple sclerosis; pharmaceutical preparations for the prevention and treatment of cranial and facial nerve disorders, connective tissue injuries, diseases and disorders, bone and cartilage injuries, diseases and disorders; pharmaceutical preparations for the prevention and treatment of neuromuscular and neurological diseases and disorders, namely, central nervous system diseases and disorders, namely central nervous system infections, brain diseases, central nervous system movement disorders, muscle diseases and disorders, namely inflammatory muscle diseases and disorders, and muscular dystrophy, ocular motility and spinal cord infections, injuries and diseases, and seizure disorders; pharmaceutical preparations for the prevention and treatment of genitourinary diseases, namely, inflammatory pelvic diseases, urological and reproductive system diseases, disorders and infections, namely, sexually transmitted diseases, erectile and sexual dysfunction, infertility and incontinence; pharmaceutical preparations for the prevention and treatment of pulmonary hypertension and pulmonary arterial hypertension; pharmaceutical preparations for the prevention and treatment of auto-immune, cardiovascular, gastrointestinal, hematologic, oncological, ophthalmological and respiratory system diseases and disorders; pharmaceutical preparations for the prevention and treatment of allergies, hypertension, menopause, diabetic neuropathy, arthritis, and pain; antibiotics, anti-infectives, anti-inflammatories, anti-fungals, anti-virals, oral and injectable pharmaceutical contraceptives, human vaccines; pharmaceutical preparations for the prevention and treatment of smoking habits and addictions; pharmaceutical preparations for the prevention and treatment of renal disease and disorders; pharmaceutical preparations for the prevention and treatment of diseases, disorders and infections of the endocrine system, namely growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of muscular atrophy; pharmaceutical preparations for the prevention and treatment of inflammatory diseases, namely inflammatory bowel diseases, inflammatory joint diseases, inflammatory connective tissue diseases, inflammatory muscle diseases and disorders; pharmaceutical preparations for the prevention and treatment of metabolic diseases and disorders, namely diabetes, gout, muscular dystrophy, sickle cell disease, and anemia; pharmaceutical preparations for the prevention and treatment of cerebrovascular diseases and digital ulcers; pharmaceutical preparations for use in dermatology, namely dermatitis, skin pigmentation diseases, psoriasis; dietary and nutritional supplements for general health and well-being; nutritional supplements for promoting weight loss; anti-aging nutritional supplements; dietary and nutritional supplements for treatment of bloating and constipation; dietary and nutritional supplements for supporting and providing energy during exercise; dietary and nutritional supplements for promoting muscle recovery after exercise; dietary and nutritional supplements for appetite suppression; nutritional supplements to aid digestion; dietary and nutritional supplements to aid sleeping and treat insomnia; dietary and nutritional supplements containing vitamins for skin, hair and nail health; dietary and nutritional supplements for relieving and reducing stress and promoting relaxation; dietary and nutritional supplements to boost the immune system; dietary and nutritional supplements to promote healthy aging; dietary and nutritional supplements for relieving bone and joint pain management; dietary and nutritional supplements for the treatment of digestive complaints, namely, IBS, Crohn's, colitis, diarrhea, hormonal imbalance, namely, menopause, polycystic ovaries, infertility, endometriosis, kidney disease, heart disease, atherosclerosis, high blood pressure, high cholesterol, liver disease, lung disease, eye diseases, namely, cataracts, macular degeneration, glaucoma, cold and flu, sore throat, stress, fatigue, headaches, migraines, muscular tension, muscle pain and memory


Classification kind code

11

Mark Details


Serial Number

1835874

Mark Type

Trademark

Legal History


Show more

Action TakenStatus
Submitted for opposition 26
on 13th Jun 2019
Approved
Submitted for opposition 27
on 26th Apr 2019
Approval Notice Sent
Submitted for opposition 12
on 07th Nov 2018
Extension of Time
Submitted for opposition 87
on 01st Nov 2018
Rep for Service Changed
Submitted for opposition 48
on 01st Nov 2018
Agent Changed
Submitted for opposition 22
on 23rd Apr 2018
Search Recorded
Submitted for opposition 20
on 23rd Apr 2018
Examiner's First Report
Submitted for opposition 31
on 10th May 2017
Formalized
Submitted for opposition 1
on 05th May 2017
Created
Submitted for opposition 30
on 04th May 2017
Filed